Prediction of Response to Therapy for Autoimmune/Inflammatory Diseases Using an Activated Macrophage-Targeted Radioimaging Agent

Molecular Pharmaceutics
Lindsay E KelderhousePhilip S Low

Abstract

The ability to select patients who will respond to therapy is especially acute for autoimmune/inflammatory diseases, where the costs of therapies can be high and the progressive damage associated with ineffective treatments can be irreversible. In this article we describe a clinical test that will rapidly predict the response of patients with an autoimmune/inflammatory disease to many commonly employed therapies. This test involves quantitative assessment of uptake of a folate receptor-targeted radioimaging agent ((99m)Tc-EC20) by a subset of inflammatory macrophages that accumulate at sites of inflammation. Murine models of four representative inflammatory diseases (rheumatoid arthritis, inflammatory bowel disease, pulmonary fibrosis, and atherosclerosis) show markedly decreased uptake of (99m)Tc-EC20 in inflamed lesions upon initiation of successful therapies, but no decrease in uptake upon administration of ineffective therapies, in both cases long before changes in clinical symptoms can be detected. This predictive capability should reduce costs and minimize morbidities associated with failed autoimmune/inflammatory disease therapies.

References

Apr 17, 1976·Lancet·R C AtkinsF E Matthews
Oct 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·R O WilliamsR N Maini
Mar 25, 1983·European Journal of Pharmacology·J A Smith
Oct 1, 1996·Immunobiology·W BrückH Lassmann
Jun 6, 1998·Experimental Neurology·S L CarlsonL Dossett
Oct 13, 1998·Alimentary Pharmacology & Therapeutics·L G AxelssonA C Bylund-Fellenius
Nov 30, 2000·Arthritis Research·R W KinneG R Burmester
Nov 21, 2002·Bioconjugate Chemistry·Christopher P LeamonNikki Douglas
Jun 18, 2003·Annals of the Rheumatic Diseases·P A Ory
Aug 23, 2003·Arthritis Research & Therapy·Peter C Taylor
Dec 24, 1955·Journal of the American Medical Association·H K BEECHER
Apr 17, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Karen S Meir, Eran Leitersdorf
Mar 4, 2005·Arthritis Research & Therapy·Wei-Tsung ChenChing-Hsuan Tung
Dec 27, 2005·Transplantation·Kate R WyburnSteven J Chadban
Apr 4, 2006·European Journal of Pharmacology·Fangping ChenJ Ren
May 2, 2006·Arthritis Research & Therapy·Chrystal M PaulosPhilip S Low
Aug 4, 2006·The Journal of Clinical Investigation·Rachael A Clark, Thomas S Kupper
Apr 4, 2007·Postgraduate Medical Journal·Annabel KuekAndrew J K Ostör
Apr 5, 2007·Nature Protocols·Stefan WirtzMarkus F Neurath
Jun 2, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Susanne ZadelaarTeake Kooistra

❮ Previous
Next ❯

Citations

Apr 17, 2016·Osteoarthritis and Cartilage·V B KrausP Mitchell
Aug 3, 2016·The Journal of Experimental Medicine·Amanda Littlewood-EvansJosé M Carballido
Nov 23, 2017·Arthritis & Rheumatology·Beth FriedmanMaripat Corr
Jun 2, 2017·Arthritis Research & Therapy·Durga M S H ChandrupatlaCarla F M Molthoff
Jan 6, 2021·Journal of Clinical Medicine·Irma Mahmutovic Persson On Behalf Of The Tristan Consortium
Sep 13, 2017·Chemical Reviews·Madduri Srinivasarao, Philip S Low

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Related Papers

Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging
Lindsay E KelderhousePhilip S Low
Advanced Drug Delivery Reviews
Philip S Low, Asok C Antony
The New England Journal of Medicine
G F Longstreth, R Green
© 2021 Meta ULC. All rights reserved